| INTRODUCTION
Byinhibitingthecontractionofuretericsmoothmuscle,α-blockers are believed to promote antegrade stone passage and reduce colic.
Alargenumberofrandomisedstudieshavebeenperformedassessing their efficacy. Up till now, the results from the majority of meta analyseshaveshownabenefitofalphablockertreatmentinincreasing stone expulsion rates and times.
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Medical expulsive therapy is now widely prescribed yet the evidence remains hotly debated. 7 In responsetheSUSPENDtrial,alargemulticentrerandomisedtrial,was conducted assessing the effectiveness of tamsulosin, nifedipine and placebointreatinguretericcalculi.
We have performed the first meta-analysis incorporating these newfindingsintotheexistingbodyofliteraturetoassessthevalueof α-blockersintreatinguretericcalculi.
| METHODS

ThisstudywasperformedusingtheguidelinessetoutbythePreferred
ReportingItemsforSystematicreviewsandMeta-Analysis(PRISMA) statement.PROSPEROregistrationnumber:CRD42015029499.
| Search strategy
Searchesofelectronicdatabases(Pubmed,Embase)wereperformed to identify relevant full texts and abstracts. Clinical trial registries (ClinicalTrials.gov;InternationalClinicalTrialsRegister)weresearched forunpublishedandemergingtrialsandauthorswerecontactedfor results.Searcheswerecompletedon20February2016.Notimerestrictionswereplacedonsearchresults.ThefollowingMeSHterms andkeywordswereusedinvariouscombinations;"urolithiasis","alpha blocker","tamsulosin","alfuzosin","medicalexpulsivetherapy","silodosin", "terazosin", "doxazosin", "calculus", "stone", "ureteric" "renal colic", "ureter* colic", "expulsive therapy", "facilitated passage". See
TableS1 for the search strategy. Reference lists were searched by handforfurthereligiblestudies.
| Inclusion criteria
AllEnglishlanguagestudiespublishedupto20February2016were includediftheymetthefollowingcriteria:
1. Patients presenting with acute ureteric colic.
Adultpatients>18years.
Singleuretericcalculus.
4.
A-blockermonotherapycomparedwithplacebo/standardtherapy.
5.
Prospective,randomisedstudies.
| Exclusion criteria
Studieswereexcludedifanyofthefollowingcriteriaweremet.
1.
Studies without original data.
Studiesinwhichα-blockerswereusedasadjuvantstolithotripsyor
surgery.
Studiesthatdidnotreportstonefreerates.
4. Animal studies.
| Quality assessment
All studies were evaluated using The Cochrane Collaboration's tool for assessing risk of bias. 8 Trialswerecategorisedintolow,intermediateandhighriskgroups. Evidence of small study effects wasfurtherevaluatedusingPeter'stest. TheNordicCentre,TheCochraneCollaboration)andStatasoftwarev.
| Data review and analysis
14(StataCorp,CollegeStation,TX,USA).
| RESULTS
The initial search for randomised studies assessing the efficacy of 
| Primary outcome analysis
Primary analysis compared α-blocker therapy to standard conserva- 
| Quality assessment
ResultsofqualityassessmentusingtheCochraneRiskofBiastoolcan befoundinFigure7.Overall,ahighdegreeofbiaswasseenwithonly nine studies judged to be at low risk [11] [12] [13] [14] [15] [16] [17] [18] [19] while41werejudgedtobe intermediate risk and17highrisk.
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F I G U R E 2 Forestplotofriskratiosofoverallstoneexpulsionrate forbiaswasblindingofbothparticipantsandpersonnelandoutcomes assessment.
| Secondary outcome analysis
The key secondary outcome measure was stone expulsion time. Functional outcomes such as analgesic usage and pain scores were poorly reported by the majority of studies preventing comprehensive analysis. Diclofenac requirements were reported by 13 studies with 909 participants. 
| DISCUSSION
The pooled results of 67 randomised trials involving 6654 participants suggests that overall α-blockers significantly increase the rate of ureteric stone passage. Use of an α-blocker is associated with a In line with previous reviews, this meta-analysis continues to demonstrateabeneficialeffectofα-blockersintreatingureterolithiasis.
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TheseresultscontrastwiththemulticentreSUSPENDtrialby Pickard etal. that did not show a benefit of α-blocker treatment. 
| CONCLUSION
Despite the results of the SUSPEND trial, α-blocker treatment for 
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